BD to Present Next Installment of BD Innovates Series: Spotlight on Pharmaceutical Systems


Werte in diesem Artikel
Aktien

156.90 EUR -2.10 EUR -1.32 %

FRANKLIN LAKES, N.J., Dec. 4, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present the next installment of its BD Innovates series, which will highlight its Pharmaceutical Systems business on Monday, December 11, 2023, at 11:30 am Eastern Time. The BD Innovates series spotlights BD's innovation, products and pipeline in support of its BD 2025 Strategy.

The live webcast of BD's presentation can be accessed from the BD investor relations website, investors.bd.com. A replay of the event will be available on the same webpage following its conclusion.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and on X (formerly known as Twitter) @BDandCo.

Contacts:




Media:

Investors:

Troy Kirkpatrick

 Adam Reiffe

VP, Public Relations

Sr. Director, Investor Relations

858.617.2361

201.847.6927

troy.kirkpatrick@bd.com      

adam.reiffe@bd.com 

 

Cision View original content:https://www.prnewswire.com/news-releases/bd-to-present-next-installment-of-bd-innovates-series-spotlight-on-pharmaceutical-systems-302005084.html

SOURCE BD (Becton, Dickinson and Company)

Aktuelle Becton, Dickinson Aktie News

Werbung

Becton, Dickinson Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Becton, Dickinson nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
Datum Rating Analyst
13.05.19 Becton, DickinsonCo (BD) Overweight Barclays Capital
07.12.18 Becton, DickinsonCo (BD) Buy Deutsche Bank AG
16.10.18 Becton, DickinsonCo (BD) Equal Weight Barclays Capital
09.03.18 Becton, DickinsonCo (BD) Market Perform BMO Capital Markets
29.12.17 Becton, DickinsonCo (BD) Buy Deutsche Bank AG

Information


Die Handels- und Depotfunktionen in diesem Broker Cockpit werden für Finanzinstrumente von der Finanzen.net Zero GmbH als vertraglich gebundener Vermittler der DonauCapital Wertpapier GmbH (§ 3 Abs. 2 WpIG) bereitgestellt; bei Kryptowerten werden die Handels- und Depotfunktionen in diesem Broker Cockpit ausschließlich von der DonauCapital Wertpapier GmbH bereitgestellt. Die Finanzen.net GmbH stellt ausschließlich den technischen Rahmen bereit und ist in die Wertpapier- und Kryptodienstleistung nicht einbezogen.